Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Intra-tracheal amikacin spray delivery in healthy mechanically ventilated piglets.

Guillon A, Darrouzain F, Heuzé-Vourc'h N, Petitcollin A, Barc C, Vecellio L, Cormier B, Lanotte P, Sarradin P, Dequin PF, Paintaud G, Ehrmann S.

Pulm Pharmacol Ther. 2019 Aug;57:101807. doi: 10.1016/j.pupt.2019.101807. Epub 2019 May 15.

PMID:
31102741
2.

In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration.

Sécher T, Dalonneau E, Ferreira M, Parent C, Azzopardi N, Paintaud G, Si-Tahar M, Heuzé-Vourc'h N.

J Control Release. 2019 Jun 10;303:24-33. doi: 10.1016/j.jconrel.2019.04.005. Epub 2019 Apr 11.

PMID:
30981816
3.

Targeting Aspergillus fumigatus Crf Transglycosylases With Neutralizing Antibody Is Relevant but Not Sufficient to Erase Fungal Burden in a Neutropenic Rat Model.

Chauvin D, Hust M, Schütte M, Chesnay A, Parent C, Moreira GMSG, Arroyo J, Sanz AB, Pugnière M, Martineau P, Chandenier J, Heuzé-Vourc'h N, Desoubeaux G.

Front Microbiol. 2019 Mar 26;10:600. doi: 10.3389/fmicb.2019.00600. eCollection 2019.

4.

Tetrafunctional Block Copolymers Promote Lung Gene Transfer in Newborn Piglets.

Caballero I, Riou M, Hacquin O, Chevaleyre C, Barc C, Pezant J, Pinard A, Fassy J, Rezzonico R, Mari B, Heuzé-Vourc'h N, Pitard B, Vassaux G.

Mol Ther Nucleic Acids. 2019 Jun 7;16:186-193. doi: 10.1016/j.omtn.2019.02.016. Epub 2019 Feb 26.

5.

Exploring the fate of inhaled monoclonal antibody in the lung parenchyma by microdialysis.

Guillon A, Pardessus J, Lhommet P, Parent C, Respaud R, Marchand D, Montharu J, De Monte M, Janiak P, Boixel C, Audat H, Huille S, Guillot E, Heuze-Vourc'h N.

MAbs. 2019 Feb/Mar;11(2):297-304. doi: 10.1080/19420862.2018.1556081. Epub 2019 Feb 4.

PMID:
30714473
6.

Lack of FcRn Impairs Natural Killer Cell Development and Functions in the Tumor Microenvironment.

Castaneda DC, Dhommée C, Baranek T, Dalloneau E, Lajoie L, Valayer A, Arnoult C, Demattéi MV, Fouquenet D, Parent C, Heuzé-Vourc'h N, Gouilleux-Gruart V.

Front Immunol. 2018 Sep 28;9:2259. doi: 10.3389/fimmu.2018.02259. eCollection 2018.

7.

Designing inhaled protein therapeutics for topical lung delivery: what are the next steps?

Bodier-Montagutelli E, Mayor A, Vecellio L, Respaud R, Heuzé-Vourc'h N.

Expert Opin Drug Deliv. 2018 Aug;15(8):729-736. doi: 10.1080/17425247.2018.1503251. Epub 2018 Jul 27. No abstract available.

PMID:
30025210
8.

Therapeutic antibodies: A new era in the treatment of respiratory diseases?

Sécher T, Guilleminault L, Reckamp K, Amanam I, Plantier L, Heuzé-Vourc'h N.

Pharmacol Ther. 2018 Sep;189:149-172. doi: 10.1016/j.pharmthera.2018.05.003. Epub 2018 May 4. Review.

PMID:
29730443
9.

Human kallikrein-related peptidase 12 stimulates endothelial cell migration by remodeling the fibronectin matrix.

Kryza T, Parent C, Pardessus J, Petit A, Burlaud-Gaillard J, Reverdiau P, Iochmann S, Labas V, Courty Y, Heuzé-Vourc'h N.

Sci Rep. 2018 Apr 20;8(1):6331. doi: 10.1038/s41598-018-24576-9.

10.

Insights on animal models to investigate inhalation therapy: Relevance for biotherapeutics.

Guillon A, Sécher T, Dailey LA, Vecellio L, de Monte M, Si-Tahar M, Diot P, Page CP, Heuzé-Vourc'h N.

Int J Pharm. 2018 Jan 30;536(1):116-126. doi: 10.1016/j.ijpharm.2017.11.049. Epub 2017 Nov 24. Review.

PMID:
29180257
11.

Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti-TNF-α Antibodies after a Single Injection in Mice.

Arnoult C, Brachet G, Cadena Castaneda D, Azzopardi N, Passot C, Desvignes C, Paintaud G, Heuzé-Vourc'h N, Watier H, Gouilleux-Gruart V.

J Immunol. 2017 Jul 15;199(2):418-424. doi: 10.4049/jimmunol.1601246. Epub 2017 Jun 5.

12.

Prolonged pharmacological inhibition of cathepsin C results in elimination of neutrophil serine proteases.

Guarino C, Hamon Y, Croix C, Lamort AS, Dallet-Choisy S, Marchand-Adam S, Lesner A, Baranek T, Viaud-Massuard MC, Lauritzen C, Pedersen J, Heuzé-Vourc'h N, Si-Tahar M, Fıratlı E, Jenne DE, Gauthier F, Horwitz MS, Borregaard N, Korkmaz B.

Biochem Pharmacol. 2017 May 1;131:52-67. doi: 10.1016/j.bcp.2017.02.009. Epub 2017 Feb 11.

PMID:
28193451
13.

Immunotherapy improves the prognosis of lung cancer: do we have to change intensive care unit admission and triage guidelines?

Guillon A, Reckamp KL, Heuzé-Vourc'h N.

Crit Care. 2017 Jan 27;21(1):18. doi: 10.1186/s13054-017-1602-8. No abstract available.

14.

Inhaled phage therapy: a promising and challenging approach to treat bacterial respiratory infections.

Bodier-Montagutelli E, Morello E, L'Hostis G, Guillon A, Dalloneau E, Respaud R, Pallaoro N, Blois H, Vecellio L, Gabard J, Heuzé-Vourc'h N.

Expert Opin Drug Deliv. 2017 Aug;14(8):959-972. doi: 10.1080/17425247.2017.1252329. Epub 2016 Nov 10. Review.

PMID:
27776446
15.

Downregulation of the neonatal Fc receptor expression in non-small cell lung cancer tissue is associated with a poor prognosis.

Dalloneau E, Baroukh N, Mavridis K, Maillet A, Gueugnon F, Courty Y, Petit A, Kryza T, Del Rio M, Guyetant S, Cadena Castaneda DC, Dhommée C, Arnoult C, Scorilas A, Gouilleux-Gruart V, Heuzé-Vourc'h N.

Oncotarget. 2016 Aug 23;7(34):54415-54429. doi: 10.18632/oncotarget.10074.

16.

Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 - April 1, 2016, Tours, France.

Desoubeaux G, Reichert JM, Sleeman M, Reckamp KL, Ryffel B, Adamczewski JP, Sweeney TD, Vanbever R, Diot P, Owen CA, Page C, Lerondel S, Le Pape A, Heuze-Vourc'h N.

MAbs. 2016 Aug-Sep;8(6):999-1009. doi: 10.1080/19420862.2016.1196521. Epub 2016 Jun 6.

17.

Development of a drug delivery system for efficient alveolar delivery of a neutralizing monoclonal antibody to treat pulmonary intoxication to ricin.

Respaud R, Marchand D, Pelat T, Tchou-Wong KM, Roy CJ, Parent C, Cabrera M, Guillemain J, Mac Loughlin R, Levacher E, Fontayne A, Douziech-Eyrolles L, Junqua-Moullet A, Guilleminault L, Thullier P, Guillot-Combe E, Vecellio L, Heuzé-Vourc'h N.

J Control Release. 2016 Jul 28;234:21-32. doi: 10.1016/j.jconrel.2016.05.018. Epub 2016 May 9.

PMID:
27173943
18.

Increment in Drug Loading on an Antibody-Drug Conjugate Increases Its Binding to the Human Neonatal Fc Receptor in Vitro.

Brachet G, Respaud R, Arnoult C, Henriquet C, Dhommée C, Viaud-Massuard MC, Heuze-Vourc'h N, Joubert N, Pugnière M, Gouilleux-Gruart V.

Mol Pharm. 2016 Apr 4;13(4):1405-12. doi: 10.1021/acs.molpharmaceut.6b00082. Epub 2016 Mar 1.

PMID:
26900766
19.

Neutrophilic Cathepsin C Is Maturated by a Multistep Proteolytic Process and Secreted by Activated Cells during Inflammatory Lung Diseases.

Hamon Y, Legowska M, Hervé V, Dallet-Choisy S, Marchand-Adam S, Vanderlynden L, Demonte M, Williams R, Scott CJ, Si-Tahar M, Heuzé-Vourc'h N, Lalmanach G, Jenne DE, Lesner A, Gauthier F, Korkmaz B.

J Biol Chem. 2016 Apr 15;291(16):8486-99. doi: 10.1074/jbc.M115.707109. Epub 2016 Feb 16.

20.

Interleukin-22 receptor is overexpressed in nonsmall cell lung cancer and portends a poor prognosis.

Guillon A, Gueugnon F, Mavridis K, Dalloneau E, Jouan Y, Diot P, Heuzé-Vourc'h N, Courty Y, Si-Tahar M.

Eur Respir J. 2016 Apr;47(4):1277-80. doi: 10.1183/13993003.01580-2015. Epub 2016 Feb 4. No abstract available.

21.

The kallikrein-related peptidase family: Dysregulation and functions during cancer progression.

Kryza T, Silva ML, Loessner D, Heuzé-Vourc'h N, Clements JA.

Biochimie. 2016 Mar;122:283-99. doi: 10.1016/j.biochi.2015.09.002. Epub 2015 Sep 4. Review.

PMID:
26343558
22.

Aerosol Therapy in Adults Receiving High Flow Nasal Cannula Oxygen Therapy.

Réminiac F, Vecellio L, Heuzé-Vourc'h N, Petitcollin A, Respaud R, Cabrera M, Pennec DL, Diot P, Ehrmann S.

J Aerosol Med Pulm Drug Deliv. 2016 Apr;29(2):134-41. doi: 10.1089/jamp.2015.1219. Epub 2015 Jul 21.

PMID:
26196740
23.

[Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].

Guilleminault L, Carmier D, Heuzé-Vourc'h N, Diot P, Pichon E.

Rev Pneumol Clin. 2015 Feb;71(1):44-56. doi: 10.1016/j.pneumo.2014.11.004. Epub 2015 Feb 14. Review. French.

PMID:
25687821
24.

Aerosol Route to Administer Teicoplanin in Mechanical Ventilation: In Vitro Study, Lung Deposition and Pharmacokinetic Analyses in Pigs.

Guillon A, Mercier E, Lanotte P, Haguenoer E, Darrouzain F, Barc C, Sarradin P, Si-Tahar M, Heuzé-Vourc'h N, Diot P, Vecellio L.

J Aerosol Med Pulm Drug Deliv. 2015 Aug;28(4):290-8. doi: 10.1089/jamp.2014.1164. Epub 2015 Jan 23.

PMID:
25616054
25.

Nebulization as a delivery method for mAbs in respiratory diseases.

Respaud R, Vecellio L, Diot P, Heuzé-Vourc'h N.

Expert Opin Drug Deliv. 2015 Jun;12(6):1027-39. doi: 10.1517/17425247.2015.999039. Epub 2015 Jan 5. Review.

PMID:
25557066
26.

Effect of formulation on the stability and aerosol performance of a nebulized antibody.

Respaud R, Marchand D, Parent C, Pelat T, Thullier P, Tournamille JF, Viaud-Massuard MC, Diot P, Si-Tahar M, Vecellio L, Heuzé-Vourc'h N.

MAbs. 2014;6(5):1347-55. doi: 10.4161/mabs.29938. Epub 2014 Oct 30.

27.

VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations.

Hervé V, Rabbe N, Guilleminault L, Paul F, Schlick L, Azzopardi N, Duruisseaux M, Fouquenet D, Montharu J, Redini F, Paintaud G, Lemarié E, Cadranel J, Wislez M, Heuzé-Vourc'h N.

MAbs. 2014;6(6):1638-48. doi: 10.4161/mabs.34454.

28.

Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system.

Guilleminault L, Azzopardi N, Arnoult C, Sobilo J, Hervé V, Montharu J, Guillon A, Andres C, Herault O, Le Pape A, Diot P, Lemarié E, Paintaud G, Gouilleux-Gruart V, Heuzé-Vourc'h N.

J Control Release. 2014 Dec 28;196:344-54. doi: 10.1016/j.jconrel.2014.10.003. Epub 2014 Oct 17.

PMID:
25451545
29.

Development of monoclonal antibodies to human kallikrein-related peptidase 6 (KLK6) and their use in an immunofluorometric assay for free KLK6.

Ott C, Ainciburu M, Parent C, Michel S, Roesch C, Vourc'h P, Corcia P, Heuze-Vourc'h N, Jolivet-Reynaud C, Courty Y.

Biol Chem. 2014 Sep;395(9):1119-26. doi: 10.1515/hsz-2014-0133.

PMID:
25153392
30.

Growth and survival of lung cancer cells: regulation by kallikrein-related peptidase 6 via activation of proteinase-activated receptor 2 and the epidermal growth factor receptor.

Michel N, Heuzé-Vourc'h N, Lavergne E, Parent C, Jourdan ML, Vallet A, Iochmann S, Musso O, Reverdiau P, Courty Y.

Biol Chem. 2014 Sep;395(9):1015-25. doi: 10.1515/hsz-2014-0124.

PMID:
24643912
31.

Angiogenesis stimulated by human kallikrein-related peptidase 12 acting via a platelet-derived growth factor B-dependent paracrine pathway.

Kryza T, Achard C, Parent C, Marchand-Adam S, Guillon-Munos A, Iochmann S, Korkmaz B, Respaud R, Courty Y, Heuzé-Vourc'h N.

FASEB J. 2014 Feb;28(2):740-51. doi: 10.1096/fj.13-237503. Epub 2013 Nov 13.

PMID:
24225148
32.

Beneficial role of overexpression of TFPI-2 on tumour progression in human small cell lung cancer.

Lavergne M, Jourdan ML, Blechet C, Guyetant S, Pape AL, Heuze-Vourc'h N, Courty Y, Lerondel S, Sobilo J, Iochmann S, Reverdiau P.

FEBS Open Bio. 2013 Jun 27;3:291-301. doi: 10.1016/j.fob.2013.06.004. Print 2013.

33.

Benign lower limb amyotrophy due to TARDBP mutation or post-polio syndrome?

Guennoc AM, Heuze-Vourc'h N, Gordon PH, Courty Y, Vourc'h P, Andres CR, Corcia P.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 Sep;14(5-6):476-8. doi: 10.3109/21678421.2013.764567. Epub 2013 Jan 28. No abstract available.

PMID:
23356346
34.

Pro-angiogenic effect of human kallikrein-related peptidase 12 (KLK12) in lung endothelial cells does not depend on kinin-mediated activation of B2 receptor.

Kryza T, Lalmanach G, Lavergne M, Lecaille F, Reverdiau P, Courty Y, Heuzé-Vourc'h N.

Biol Chem. 2013 Mar;394(3):385-91. doi: 10.1515/hsz-2012-0291.

PMID:
23152405
35.

Tenascin-W is a better cancer biomarker than tenascin-C for most human solid tumors.

Brellier F, Martina E, Degen M, Heuzé-Vourc'h N, Petit A, Kryza T, Courty Y, Terracciano L, Ruiz C, Chiquet-Ehrismann R.

BMC Clin Pathol. 2012 Sep 4;12:14. doi: 10.1186/1472-6890-12-14.

36.

Monitoring of tumour progression using bioluminescence imaging and computed tomography scanning in a nude mouse orthotopic model of human small cell lung cancer.

Iochmann S, Lerondel S, Bléchet C, Lavergne M, Pesnel S, Sobilo J, Heuzé-Vourc'h N, Le Pape A, Reverdiau P.

Lung Cancer. 2012 Jul;77(1):70-6. doi: 10.1016/j.lungcan.2012.01.009. Epub 2012 Feb 8.

PMID:
22321610
37.

Inhibition of Wnt/β-catenin signaling by a soluble collagen-derived frizzled domain interacting with Wnt3a and the receptors frizzled 1 and 8.

Hendaoui I, Lavergne E, Lee HS, Hong SH, Kim HZ, Parent C, Heuzé-Vourc'h N, Clément B, Musso O.

PLoS One. 2012;7(1):e30601. doi: 10.1371/journal.pone.0030601. Epub 2012 Jan 27. Erratum in: PLoS One. 2012;7(3). doi:10.1371/annotation/bd37b3ad-c242-4e77-9ef3-8e92d1f105f5.

38.

Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors.

Guillon-Munos A, Oikonomopoulou K, Michel N, Smith CR, Petit-Courty A, Canepa S, Reverdiau P, Heuzé-Vourc'h N, Diamandis EP, Courty Y.

J Biol Chem. 2011 Jul 22;286(29):25505-18. doi: 10.1074/jbc.M110.213231. Epub 2011 May 31.

39.

The airways, a novel route for delivering monoclonal antibodies to treat lung tumors.

Maillet A, Guilleminault L, Lemarié E, Lerondel S, Azzopardi N, Montharu J, Congy-Jolivet N, Reverdiau P, Legrain B, Parent C, Douvin DH, Hureaux J, Courty Y, De Monte M, Diot P, Paintaud G, Le Pape A, Watier H, Heuzé-Vourc'h N.

Pharm Res. 2011 Sep;28(9):2147-56. doi: 10.1007/s11095-011-0442-5. Epub 2011 Apr 14.

PMID:
21491145
40.

Alternative splicing variant of kallikrein-related peptidase 8 as an independent predictor of unfavorable prognosis in lung cancer.

Planque C, Choi YH, Guyetant S, Heuzé-Vourc'h N, Briollais L, Courty Y.

Clin Chem. 2010 Jun;56(6):987-97. doi: 10.1373/clinchem.2009.138917. Epub 2010 Apr 1.

41.

TFPI-2 silencing increases tumour progression and promotes metalloproteinase 1 and 3 induction through tumour-stromal cell interactions.

Gaud G, Iochmann S, Guillon-Munos A, Brillet B, Petiot S, Seigneuret F, Touzé A, Heuzé-Vourc'h N, Courty Y, Lerondel S, Gruel Y, Reverdiau P.

J Cell Mol Med. 2011 Feb;15(2):196-208. doi: 10.1111/j.1582-4934.2009.00989.x.

42.

Effect of the oligodendrocyte myelin glycoprotein (OMgp) on the expansion and neuronal differentiation of rat neural stem cells.

Martin I, Andres CR, Védrine S, Tabagh R, Michelle C, Jourdan ML, Heuze-Vourc'h N, Corcia P, Duittoz A, Vourc'h P.

Brain Res. 2009 Aug 11;1284:22-30. doi: 10.1016/j.brainres.2009.05.070. Epub 2009 Jun 6.

PMID:
19501059
43.

Quantitative RT-PCR analysis and immunohistochemical localization of the kallikrein-related peptidases 13 and 14 in lung.

Planque C, Bléchet C, Ayadi-Kaddour A, Heuzé-Vourc'h N, Dumont P, Guyétant S, Diamandis EP, El Mezni F, Courty Y.

Biol Chem. 2008 Jun;389(6):781-6. doi: 10.1515/BC.2008.089.

PMID:
18627302
44.

Extracellular catalase activity protects cysteine cathepsins from inactivation by hydrogen peroxide.

Hervé-Grépinet V, Veillard F, Godat E, Heuzé-Vourc'h N, Lecaille F, Lalmanach G.

FEBS Lett. 2008 Apr 16;582(9):1307-12. doi: 10.1016/j.febslet.2008.03.007. Epub 2008 Mar 14.

45.

Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization.

Maillet A, Congy-Jolivet N, Le Guellec S, Vecellio L, Hamard S, Courty Y, Courtois A, Gauthier F, Diot P, Thibault G, Lemarié E, Heuzé-Vourc'h N.

Pharm Res. 2008 Jun;25(6):1318-26.

PMID:
18030605
46.

Expression of the human kallikrein genes 10 (KLK10) and 11 (KLK11) in cancerous and non-cancerous lung tissues.

Planque C, Aïnciburu M, Heuzé-Vourc'h N, Régina S, de Monte M, Courty Y.

Biol Chem. 2006 Jun;387(6):783-8.

PMID:
16800740
47.

Recombinant kallikrein expression: site-specific integration for hK6 production in human cells.

Heuzé-Vourc'h N, Aïnciburu M, Planque C, Brillard-Bourdet M, Ott C, Jolivet-Reynaud C, Courty Y.

Biol Chem. 2006 Jun;387(6):687-95. Review.

PMID:
16800729
48.

IL-4 regulates COX-2 and PGE2 production in human non-small cell lung cancer.

Cui X, Yang SC, Sharma S, Heuze-Vourc'h N, Dubinett SM.

Biochem Biophys Res Commun. 2006 May 19;343(4):995-1001. Epub 2006 Mar 23.

PMID:
16574063
49.

Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer.

Dalwadi H, Krysan K, Heuze-Vourc'h N, Dohadwala M, Elashoff D, Sharma S, Cacalano N, Lichtenstein A, Dubinett S.

Clin Cancer Res. 2005 Nov 1;11(21):7674-82.

50.

Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells.

Baratelli F, Lin Y, Zhu L, Yang SC, Heuzé-Vourc'h N, Zeng G, Reckamp K, Dohadwala M, Sharma S, Dubinett SM.

J Immunol. 2005 Aug 1;175(3):1483-90.

Supplemental Content

Loading ...
Support Center